Merck
Phase III data presented at the WCLC suggests the new VEGF and PD-L1 inhibitor could prolong progression-free survival versus Merck's anti-PD-1 blockbuster.
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
Merck Terminates Phase III Trials of Keytruda in Certain Cancers
The trials failed to show benefits compared to placebo during prespecified interim analyses.
New analyses from the Phase I trial of mRNA-4157 shed light on lasting immune responses, toxicity profiles, and treatment feasibility.
Merck, Daiichi Sankyo to Add DLL3-Targeted T-Cell Engager to Drug Development Pact
Under the terms of the expanded deal, Merck will receive an upfront cash payment of $170 million, and the firms will share profits and expenses outside Japan.